US FDA Panel Recommends against Approving Pfizer-Biontech Booster Shot
The FDA decision comes as global debate intensifies over whether and for whom booster shots are needed.
The US Food and Drug Administration's scientific advisory committee unanimously recommended against approving a booster shot of the Pfizer-BioNTech coronavirus vaccine for people aged 16 and up.
After a day-long public debate on whether booster shots are necessary and, if so, for whom, the committee voted 16 to 2.
Biden’s administration had hoped that the FDA would approve a third shot of the Pfizer vaccine in time, for booster shots to be distributed to Pfizer recipients next week.
A committee member and official at the National Institutes of Health Dr. Michael G. Kurilla said, “It’s unclear that everyone needs to be boosted, other than a subset of the population that clearly would be at high risk for serious disease.”
Local media stressed that the recommendation was the latest in a series of setbacks for the US President’s booster plan since he first announced it a month ago.